The survey for the DT Report 2026 is now available – Take part and help shape the future of diabetes technology with...
DCB joins the OPEN project: evidence on the clinical and person-reported outcomes of open-source automated insulin delivery (AID) system users
DCB joins the OPEN project: evidence on the clinical and person-reported outcomes of open-source automated insulin delivery (AID) system users
Bern, September 14, 2022 – DCB has become a new consortium member of the OPEN project – a patient-led research project gathering real-world evidence on the clinical and quality of life outcomes of open-source automated insulin delivery (AID) system users to better understand their impact on the lives of people with diabetes.
Today, modern therapy methods such as sensors for continuous glucose monitoring and insulin pumps are available for people with diabetes in selected countries. Nevertheless, only a small proportion of people with diabetes reach the long-term outcome parameters recommended by therapeutic guidelines of an hemoglobin A1c value <7.0%. In closed-loop systems, also known as “artificial pancreas” or “automated insulin delivery” (AID) systems, a control algorithm continuously and automatically adjusts insulin dosing of an insulin pump according to an individual’s predicted glucose levels and insulin needs.
However, research, commercial development and regulatory approval of such technologies are resource heavy, time consuming and complex. Under the mantra #WeAreNotWaiting, tech-savvy people with diabetes have therefore started building their own AID systems. Based on the principle of “paying it forward”, instructions and code needed to build and maintain these systems as well as community peer-support are freely available on open-source platforms online.
Photo: Researchers of the OPEN project
The team found that people who are using these systems not only experienced significant improvements of their physical, but also tremendous improvements in the quality of life and sleep. OPEN has moreover established an international consensus statement of 48 healthcare professionals and legal experts that provides theoretical background and practical guidance for healthcare professionals who wish to support individuals using open-source AID, which was part of the “100 years of insulin” special issue of The Lancet.
An international consortium of well-established research and patient advocacy organisations
With DCB joining the OPEN project in June 2022, the consortium now consists of 11 members, including the University College Dublin, Charité – Universitätsmedizin Berlin, Dedoc Labs GmbH, the Australian Centre for Behavioural Research in Diabetes, the University of Copenhagen, Stanford University, and King’s College London.
Visual: The OPEN consortium (Status: September 2022)
About OPEN
The OPEN project consists of an international and cross-cutting and patient-led consortium that aims to build an evidence base around the impact of open-source AID systems on people with diabetes across several regions of the world.
Media contacts
Sunjoy Mathieu & Greta Ehlers
Hanne Ballhausen
More recent news
DT-Report 2026: Join now
Alva Innovation wins the DCB Open Innovation Challenge 2025
Bern, 6 November 2025 - The start-up Alva Innovations has won first place in the DCB Open Innovation Challenge. The...
A Day of Innovation: Swiss Diabetes Technology and Beyond
Join us on 5 November 2025 at sitem-insel, Bern for a day dedicated to inspiring ideas and new perspectives in perspectives in medtech, diabetes technology and beyond.



